2480 Stock Overview
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Beijing Luzhu Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$20.95 |
| 52 Week High | HK$38.20 |
| 52 Week Low | HK$17.00 |
| Beta | 0 |
| 11 Month Change | -15.86% |
| 3 Month Change | -8.32% |
| 1 Year Change | -38.65% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2480 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.3% | 2.2% | 1.6% |
| 1Y | -38.7% | -13.1% | 10.1% |
Return vs Industry: 2480 underperformed the Hong Kong Biotechs industry which returned -11.2% over the past year.
Return vs Market: 2480 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 2480 volatility | |
|---|---|
| 2480 Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2480 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2480's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 148 | Jian Kong | luzhubiotech.com |
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. Its clinical-stage product candidates include LZ901, a recombinant herpes zoster vaccine; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection product for the treatment of various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection to treat B cell leukemia and lymphoma. The company’s pre-clinical-stage product candidates comprise Recombinant Varicella vaccine for the prevention of varicella in children; Recombinant Syncytial Virus (RSV) vaccine for the indication of RSV-induced lower respiratory tract disease; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932 bispecific antibody to treat lymphoma.
Beijing Luzhu Biotechnology Co., Ltd. Fundamentals Summary
| 2480 fundamental statistics | |
|---|---|
| Market cap | HK$4.21b |
| Earnings (TTM) | -HK$300.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.0x
P/E RatioIs 2480 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2480 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥279.94m |
| Earnings | -CN¥279.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.8% |
How did 2480 perform over the long term?
See historical performance and comparison